The FDA accepted the investigational new drug application for UGN-103 in April 2024. These new positive data position the ...
Daratumumab and hyaluronidase-fihj received FDA approval for high-risk smoldering multiple myeloma, showing significant PFS ...
Jason S. Starr, DO, assistant professor of medicine and a hematologist/oncologist in the Department of Internal Medicine at ...
In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...
Regarding efficacy, the phase 1 trial showed impressive objective response rates (ORR), approaching 70%. Typical PRRT alone ...
The management of advanced thyroid cancer requires careful consideration of histology, molecular profiling, and treatment ...
A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.
The combination of talquetamab (Talvey) and daratumumab (Darzalex) demonstrated promising and robust clinical activity for the treatment of patients with heavily pretreated, relapsed/refractory ...
1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...
M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback